Locanabio, Inc.
26 articles about Locanabio, Inc.
-
Locanabio Announces Presentation of Preclinical Data Demonstrating an Improved Vectorized snRNA Platform
10/6/2023
Locanabio, Inc. today announced the presentation of data demonstrating the packaging and delivery of its proprietary small nuclear RNA (snRNA) platform using adeno-associated virus (AAV).
-
Locanabio Announces Participation in Chardan’s 7th Annual Genetic Medicines Conference
9/25/2023
Locanabio, Inc. today announced that Jim Burns, Ph.D., Locanabio’s chief executive officer, will provide a corporate overview at 5:30 pm. ET on Monday, October 2nd at Chardan’s 7th Annual Genetic Medicines Conference which is being held in New York City.
-
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
5/16/2023
Locanabio, Inc. announced the presentation of data from its lead vectorized snRNA exon skipping program, LBIO-115, in development for the treatment of Duchenne muscular dystrophy.
-
Locanabio Announces Equity Investment from CureDuchenne Ventures to Support Development of snRNA Exon Skipping Approach for Duchenne Muscular Dystrophy (DMD)
5/15/2023
Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, announced that CureDuchenne Ventures, the strategic investment arm of CureDuchenne, has made an equity investment in Locanabio.
-
Locanabio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
5/2/2023
Locanabio, Inc. today announced that data from LBIO-115, its vectorized snRNA exon skipping program in development for the treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, and its Cas13d-mediated program for C9orf72-related amyotrophic lateral sclerosis (ALS) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.
-
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
4/20/2023
Locanabio, Inc. announced the first presentation of data from its next generation engineered small nuclear RNA, or snRNA, platform, which is designed to efficiently deliver targeted snRNA payloads via an adeno-associated virus for long-term therapeutic expression.
-
As the American Society of Gene & Cell Therapy's 25th Annual Meeting wraps up, a host of life science companies touted their research and products. BioSpace looks at some of them.
-
Locanabio's Proprietary CORRECTx™ RNA-Targeting Gene Therapy Reduces Disease-Causing Hexanucleotide Repeat Expansions in a Model of Amyotrophic Lateral Sclerosis
5/19/2022
Oral presentation of new preclinical data at American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.
-
Locanabio to Present New Preclinical Data Demonstrating Application of CORRECTx™ Platform for Treating Amyotrophic Lateral Sclerosis at American Society of Gene and Cell Therapy 25th Annual Meeting
5/2/2022
Locanabio, Inc. today announced that new data from preclinical research of its proprietary CORRECTx™ platform in C9ORF72-mediated amyotrophic lateral sclerosis (ALS) will be highlighted in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.
-
Locanabio to Present at 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced that Jim Burns, PhD, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 11:30 a.m. ET.
-
Locanabio to Participate in Upcoming Investor Conferences - Nov 22, 2021
11/22/2021
Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, announced that its leadership team will participate in the following upcoming investor conferences.
-
Locanabio Presents New Preclinical Data from Myotonic Dystrophy Type 1 Program at Society for Muscle Biology Frontiers in Myogenesis Conference 2021
11/18/2021
Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced the presentation of new preclinical data from its myotonic dystrophy type 1 (DM1) program.
-
Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Locanabio Expands Leadership Team with Appointment of Kat Lange as Chief Financial Officer
9/7/2021
Locanabio, Inc. today announced the appointment of Kat Lange as chief financial officer.
-
BioSpace Movers & Shakers, April 3
4/3/2020
Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers. -
Locana Expands Leadership Team with Appointment of Micah Mackison, as Chief Business Officer
4/1/2020
Locana, Inc., a leading RNA-targeting gene therapy company, announced the appointment of Micah Mackison, as Chief Business Officer.
-
BioSpace Movers & Shakers, Dec. 13
12/13/2019
Pharma and biotech companies strengthen their leadership teams and boards with this week's hires. -
Locana Bio Expands Leadership Team with Appointment of former Casebia CEO, James Burns, Ph.D., as Chief Executive Officer
12/10/2019
Locana, Inc., a leading RNA-targeting gene therapy company, announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding the experienced leadership team and as part of a planned transition of the company’s director and recent CEO, Jeffrey M. Ostrove, Ph.D., to continue service as director..
-
Locana Expands Leadership Team with Appointment of former Casebia CEO, James Burns, Ph.D., as Chief Executive Officer
12/10/2019
Locana, Inc. announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding the experienced leadership team and as part of a planned transition of the company's director and recent CEO, Jeffrey M. Ostrove, Ph.D., to continue service as director..